Last reviewed · How we verify
Placebo matched to MK-8527
This is a placebo control arm and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo matched to MK-8527 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo matched to MK-8527 is an inert formulation designed to match the appearance, taste, and administration route of the active investigational drug MK-8527 for blinded clinical trial purposes. It allows for comparison of MK-8527's efficacy and safety against a control group receiving no active treatment. The specific mechanism of action cannot be determined from the placebo itself.
Approved indications
Common side effects
Key clinical trials
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (PHASE3)
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (PHASE3)
- Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to MK-8527 CI brief — competitive landscape report
- Placebo matched to MK-8527 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI